The clinical study aims to evaluate a vaccine for avian influenza A (H7N9) delivered by Vaxxas’ high-density microarray patch (HD-MAP), and is funded by the United States government as a potential ...

Publication in PLoS Medicine reveals groundbreaking clinical research on broad potential of novel high-density microarray patch (HD-MAP) to efficiently deliver vaccines directly to the skin, enhancing ...

Recently published data generated by researchers at The University of Queensland and Vaxxas shows effective delivery of a nucleic acid-based COVID-19 vaccine in a preclinical animal study utilizing ...

Vaxxas has received a manufacturing licence from Australia’s Therapeutic Goods Administration (TGA) for its high-density microarray patch (HD-MAP) for clinical studies at a biomedical facility in ...

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that research demonstrating the ...

The MarketWatch News Department was not involved in the creation of this content. -- Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian ...

Self-administration of vaccines using the Vaxxas high-density microarray patch (HD-MAP) could reduce the need for healthcare workers to administer vaccines, expanding the rate, broadening the scope, ...

Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...